Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Alter, M; Satzger, I; Schrem, H; Kaltenborn, A; Kapp, A; Gutzmer, R.
Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
J Dtsch Dermatol Ges. 2014; 12(6): 480-488.
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Schrem Harald Heinrich
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Organ transplant recipients are prone to the development of non-melanoma skin cancer. Organ transplant recipients often develop multiple non-melanoma skin cancers and the tumors show an aggressive growth pattern, therefore surgical therapy can be difficult. Switch of the immunosuppressive regimen to mTOR-inhibitors such as everolimus or sirolimus can have an antitumor effect. In a monocentric retrospective study we evaluated organ transplant recipients who presented with non-melanoma skin cancer in the years 2008-2010. Experience with patients who were switched to an mTOR-inhibitor due to non-melanoma skin cancer are reported in detail, and recent clinical studies are reviewed. 60 organ transplant recipients with non-melanoma skin cancer were evaluated. Due to the development of multiple non-melanoma skin cancer within a few years, the immunosuppressive regimen was switched to everolimus in 7 patients and to sirolimus in 5 patients. Eight patients were evaluable for the effect of mTOR-inhibitors on the development of non-melanoma skin cancer; 4 patients had to discontinue the medication with mTOR-inhibitors early due to various side effects. In the year before the switch to mTOR-inhibitors, 8 patients developed 16 squamous cell carcinomas, 3 Basal cell carcinomas and 22 cases of Bowen's disease. All tumors were histologically confirmed. In the year after switch of immunosuppression, the rate of squamous cell carcinomas (n = 2) and Bowen's disease (n = 3), but not of basal cell carcinomas (n = 2) was significantly reduced. Moreover, 5 prospective randomized trials recently have demonstrated a reduced number of non-melanoma skin cancers in organ transplant recipients after switch of the immunosuppressive regimen to mTOR-inhibitors. Switch of the immunosuppressive regimen to mTOR-inhibitors should be considered for organ transplant recipients suffering from multiple non-melanoma skin cancers. © 2014 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Bowen's Disease - diagnosis
Bowen's Disease - prevention & control
Carcinoma, Basal Cell - diagnosis
Carcinoma, Basal Cell - prevention & control
Drug Substitution -
Everolimus -
Female -
Humans -
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Male -
Middle Aged -
Organ Transplantation -
Postoperative Complications - diagnosis
Postoperative Complications - prevention & control
Randomized Controlled Trials as Topic -
Retrospective Studies -
Sirolimus - adverse effects
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Skin Neoplasms - diagnosis
Skin Neoplasms - prevention & control

© Meduni Graz Impressum